True Wealth Design LLC Sells 3,274 Shares of United Therapeutics Co. (NASDAQ:UTHR)

True Wealth Design LLC lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 95.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 169 shares of the biotechnology company's stock after selling 3,274 shares during the period. True Wealth Design LLC's holdings in United Therapeutics were worth $61,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Renaissance Technologies LLC grew its stake in shares of United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company's stock worth $692,748,000 after acquiring an additional 22,978 shares in the last quarter. FMR LLC grew its position in United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock worth $386,168,000 after purchasing an additional 314,004 shares in the last quarter. LSV Asset Management increased its stake in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock valued at $307,837,000 after buying an additional 436,851 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company's stock worth $186,656,000 after buying an additional 22,683 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its stake in shares of United Therapeutics by 0.9% in the 3rd quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company's stock worth $203,078,000 after buying an additional 4,869 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In related news, Director Nilda Mesa sold 224 shares of the business's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $412.28, for a total value of $92,350.72. Following the completion of the sale, the director now owns 5,783 shares in the company, valued at $2,384,215.24. The trade was a 3.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 127,227 shares of company stock valued at $47,398,820. 11.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently commented on UTHR shares. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Wells Fargo & Company lifted their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 20th. Jefferies Financial Group raised their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. LADENBURG THALM/SH SH boosted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Finally, Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

United Therapeutics Stock Performance

NASDAQ UTHR traded down $7.64 during trading hours on Friday, hitting $370.49. The company had a trading volume of 211,330 shares, compared to its average volume of 339,426. The firm has a 50 day simple moving average of $367.77 and a 200 day simple moving average of $335.65. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm has a market capitalization of $16.54 billion, a price-to-earnings ratio of 16.27, a PEG ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. During the same quarter in the previous year, the company earned $5.38 earnings per share. United Therapeutics's revenue for the quarter was up 22.9% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.